American Journal of Psychiatry

Article	Citations
Highlights From the Residents’ Journal: December 2021	531
Treating Pathologies of the Will	228
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	169
Evaluating Associations Between Cannabis and Heroin Use	158
Broadening the Parameters of Clinical High Risk for Psychosis	143
2024 Annual Meeting: Presidential Address	134
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	130
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	129
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	128
Depression, Inflammation, and Postpartum Psychosis	116
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	109
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	106
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	104
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	101
Mental Health Disparities Research: An Introduction to New Directions	93
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	93
Intentional Drug Overdose Deaths in the United States	89
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	89
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	89
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	85
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	83
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	79
Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder	77
Correcting Overestimations in Self-Harm Visit Data	74
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	73

Suicide and the Menstrual Cycle	73
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	69
Correction to Poirot et al.	68
Corrigendum to Morley et al.	65
2024 Annual Meeting: CEO and Medical Director’s Address	64
New Insights Into Psychotic Disorders	63
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	63
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	62
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	61
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	60
Highlights From the Residents’ Journal: September 2024	60
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	58
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	58
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	57
Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial	56
The First Large GWAS Meta-Analysis for Postpartum Depression	55
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	54
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	53
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	52
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	51
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	50
Familial Risk of Postpartum Psychosis	50
Coordinate Network Mapping: An Emerging Approach for Morphometric Meta-Analysis	50
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	49
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	48
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	47
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	47
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	46
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	46
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	45
Comment on “Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank”	45
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	45
From Crisis to Action: Psychiatry’s Ethical Imperative to Defend Transgender People’s Rights, Dignity, and Access to Care	45
The Neglected Role of Psychotherapy for Treatment-Resistant Depression	42
Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies	42
Alcohol and the Etiology of Depression	42
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	42
Risk of Incident Psychosis and Mania With Prescription Amphetamines	40
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	40
Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial	39
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	39
Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome	39
2021 Articles of Import and Impact	38
Toward Inclusive, Evidence-Based rTMS Care for Patients With Co-Occurring Substance Use Disorders: Response to Steele et al.	38
Suicide in Black Females	37
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	36
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	36
Psilocybin: From Psychiatric Pariah to Perceived Panacea	36
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder	36
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	36

Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	35
Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	35
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	35
Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia	35
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	35
Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	34
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	34
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	34
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	34
Neuromodulation Strategies for the Treatment of Depression	34
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	33
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	33
Correction to Baum et al.	33
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	32
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	32
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	32
When Will There Be Good News?	31
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	31
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	31
Beneath the Phenotypic Surface: Pleiotropy Shapes the Co-Occurrence of Alcohol Use Disorder and Psychopathology	31
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	30
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	30
Toward Precision Noninvasive Brain Stimulation	30
Innovative Directions to Advance Mental Health Disparities Research	30
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	30
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	29
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	29
Interindividual Differences in Cortical Thickness and Their Genomic Underpinnings in Autism Spectrum Disorder	29
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	29
The Amygdala and Depression: A Sober Reconsideration	28
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	28
Correction	27
Auditory Steady-State Responses Probe GABA-Related Oscillatory Cortical Circuits and Their Relation to Neurodevelopmental Mental Disorders	27
2024 Articles of Import and Impact	26
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	26
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	25
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	25
Ketamine After Two Antidepressants?	25
Highlights From the Residents’ Journal: December 2024	25
Progress and Challenges in GxE Research on Depression	24
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg	24
Recommendations for the Usage of Ketamine and Esketamine	24
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	24
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	24
Functional Connectivity Mapping for rTMS Target Selection in Depression	24
Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence	23
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	23
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them	23
Technology and Mental Health: State of the Art for Assessment and Treatment	23
Cannabis Use and the Endocannabinoid System: A Clinical Perspective	23
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial	23
Adolescent Suicidality and Depression, Premenstrual Dysphoric Disorder, and Safety Issues Related to Ketamine and Esketamine Treatment	23
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	23
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	22
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	22
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	22
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon	22
Perinatal Mental Health: Advances and Opportunities	22
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	22
Antidepressants and Bipolar Disorder: The Plot Thickens	21
Vaccines as Immunotherapies for Substance Use Disorders	21
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?	21
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	21
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	21
Psychotropic Drug–Related Weight Gain and Its Treatment	20
Highlights From the Residents’ Journal: September 2023	20
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	20
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	20
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	20
Improved Response Inhibition Through Cognition-Guided EEG Neurofeedback in Men With Methamphetamine Use Disorder	20
An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	19
Neglect of Adverse Effects in Treatment Guidelines for Depression	19
Focusing on Substance Use Disorders, Opioids, and Craving	19
Don’t Throw the Baby Out With the Bathwater: A Need for Nuanced Practice and Additional Research on Telehealth Management of ADHD	18
Inner-Directed Therapy in MDMA-Assisted Psychotherapy	18
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	18
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	18
Polygenic Risk Scores and Genetics in Psychiatry	18
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	18
Effects of County-Level Opioid Dispensing Rates on Individual-Level Patterns of Prescription Opioid and Heroin Consumption: Evidence From National U.S. Data	18

Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	18
Putting Genetics to Work in the Psychiatric Clinic	18
Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	18
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	18
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	17
Disclosure of Editors’ Financial Relationships	17
Increased Inflammation in Depression: A Little in All, or a Lot in a Few?	17
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	17
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial	17
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	17
Reports to the Membership	17
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	16
Intergenerational Effects of the Fast Track Intervention on Next-Generation Child Outcomes: A Preregistered Randomized Clinical Trial	16
Highlights From the Residents’ Journal: June 2025	16
Beyond the Landmarks: Where to Next With Biomarkers of Autism?	15
Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark	15
Treating Depression With Repetitive Transcranial Magnetic Stimulation: A Clinician’s Guide	15
New Insights Into Major Depression and the Treatment of Bipolar Depression	15
Association Between Polygenic Risk Scores and Outcome of ECT	15
MDMA and MDMA-Assisted Therapy	15
Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems	15
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?	15
Psychosis Risk With Prescription Amphetamine	15
An Honest Reckoning With the Amygdala and Mental Illness	15
Prospective Associations Between Structural Brain Development and Onset of Depressive Disorder During Adolescence and Emerging Adulthood	15